🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Feinberg has been selected as the home of the Journal of Clinical Investigation (Journal of Clinical Investigation) for its next five-year term, and Elizabeth McNally, MD, PhD, will serve as the journal’s next editor-in-chief. spr.ly/6015JvVXN

Welcome to new faculty ⁦Lurie Cancer Center⁩ Dr Niraj K. Shenoy—GU Oncologist, cancer biologist, and Dir of kidney cancer research. Enjoyed learning about his journey and his research. If you see him in the hallways give him our warm purple welcome ⁦June M⁩

.Daniel Brat, MD, PhD, MD, PhD, chair of Northwestern Pathology and a member of Lurie Cancer Center, has been heavily involved in the process of moving molecular genetic #biomarkers for #glioma from the lab to clinical practice. Read more: news.feinberg.northwestern.edu/2022/03/pathol… via Northwestern Feinberg School of Medicine #neuropath

The seven priority areas in President Donald J. Trump’s Cancer Moonshot 2.0 initiative.

Small but mighty! This is a video of a killer T cell of the immune system destroying a monstrous ovarian cancer cell. I recently captured this data on a spinning disc confocal microscope.

Thank you so much, Lynne Elmore. It was great having you here. Could not be more grateful to ACS Research for all the support!

Congratulations to Lurie Cancer Center’s Rebecca Luchtel, PhD, on receiving a 2023 ASH Scholar Award! Learn more about this prestigious research award at: hematology.org/newsroom/press… #ASHKudos

Thank you so much, Lynne! It was great connecting as always!

Does the addition of ipilimumab to standard-dose nivolumab safely improve clinical outcomes in patients with advanced cancers other than melanoma? Read the findings from Lurie Cancer Center investigators Niraj Shenoy, MD, PhD, MS and Anthony Serritella in JAMA Oncology jamanetwork.com/journals/jamao…

Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma jamanetwork.com/journals/jamao…

Important analysis to inform benefit:risk assessment for patients!

A meta-analysis from Niraj Shenoy, MD, PhD, MS in JAMA Oncology revealed that in advanced cancers other than melanoma, the addition of ipilimumab to standard-dose nivolumab was not associated with clinically meaningful improvement. news.feinberg.northwestern.edu/2023/09/21/com… Anthony Serritella

Big problem of IO access in control arm as trial was performed in countries lacking access. 40% of patients in control arm who got systemic therapy at relapse didn’t get IO. Censoring also an issue. The “positive” OS isn’t real. More info here…..ascopubs.org/doi/full/10.12…

While the LMIC exploitation component is perhaps debatable (if one considers the flawed argument of local SoC), that the knowingly inferior control arms constitute a mockery of science is not.

Hypoxia inducible factors drive miRNA-mediated downregulation of L2HGDH and HIF1A in clear cell renal cancer independent of 14q deletion biorxiv.org/content/10.110…

Latest preprint from the Shenoy Lab: In vivo anti-tumor activity of high-dose parenteral ascorbic acid is mediated primarily via cofactor activity, not via oxidative stress. biorxiv.org/content/10.110…